

09/117246

12 Rec'd PCT/PTO 27 JUL 1998


Certificate of Mailing

Date of Deposit July 27, 1998Label Number: EH858744018US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20231.


Sandra E. Marxen

Printed name of person mailing correspondence

Signature of person mailing correspondence

Substitute Form PTO 1390 U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket Number: <u>50062/004001</u>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application Number: NOT YET KNOWN
INTERNATIONAL APPLICATION NUMBER		INTERNATIONAL FILING DATE
<u>PCT/FR97/00167</u>		<u>January 28, 1997</u>
PRIORITY DATE CLAIMED		<u>January 29, 1996</u>
TITLE OF INVENTION:		AMINO ACID-ENRICHED PLANT PROTEIN RESERVES, PARTICULARLY LYSINE-ENRICHED MAIZE γ -ZEIN, AND PLANTS EXPRESSING SUCH PROTEINS
APPLICANTS FOR DO/EO/US:		Dolores Ludevid, Margarita Torrent, Inaki Alvarez, Pascual Perez
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1.	<input checked="" type="checkbox"/>	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2.	<input type="checkbox"/>	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3.	<input checked="" type="checkbox"/>	This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19 th month from the earliest claimed priority date.
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
a.	<input checked="" type="checkbox"/>	is transmitted herewith (required only if not transmitted by the International Bureau).
b.	<input type="checkbox"/>	has been transmitted by the International Bureau.
c.	<input type="checkbox"/>	Is not required, as the application was filed with the United States Receiving Office (RO/US).
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7.	<input type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).
a.	<input type="checkbox"/>	are transmitted herewith (required only if not transmitted by the International Bureau).
b.	<input type="checkbox"/>	have been transmitted by the International Bureau.
c.	<input type="checkbox"/>	have not been made; however, the time limit for making such amendments has NOT expired.
d.	<input checked="" type="checkbox"/>	have not been made and will not be made.
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.	<input checked="" type="checkbox"/>	An oath or declaration of the inventors (35 U.S.C. 371(c)(4)), UNSIGNED.

10.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).																																																								
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.																																																								
12.		An assignment for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.																																																								
13.		A FIRST preliminary amendment.																																																								
		A SECOND or SUBSEQUENT preliminary amendment.																																																								
14.		A substitute specification.																																																								
15.		A change of power of attorney and/or address letter.																																																								
16.		Other items or information:																																																								
17.	X	<p>The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(5)):</p> <table> <tr> <td>Search Report has been prepared by the EPO or JPO</td> <td>\$ 930.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.482)</td> <td>\$ 720.00</td> </tr> <tr> <td>No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO</td> <td>\$ 790.00</td> </tr> <tr> <td>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO</td> <td>\$ 1070.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)</td> <td>\$ 98.00</td> </tr> </table> <p>ENTER APPROPRIATE BASIC FEE AMOUNT = \$1,070.00</p> <p>Surcharge of \$130 for furnishing the oath or declaration later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>[**] - 20 =</td> <td></td> <td>x \$22.00</td> </tr> <tr> <td>Independent claims</td> <td>[**] - 3 =</td> <td></td> <td>x \$82.00</td> </tr> <tr> <td>Multiple dependent claims (if applicable)</td> <td></td> <td></td> <td>+ \$270.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS = \$ 1,070.00</td> </tr> <tr> <td colspan="4">Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).</td> </tr> <tr> <td colspan="4">SUBTOTAL = \$ 1,070.00</td> </tr> <tr> <td colspan="4">Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</td> </tr> <tr> <td colspan="4">TOTAL NATIONAL FEE = \$ 1,070.00</td> </tr> <tr> <td colspan="4">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.</td> </tr> <tr> <td colspan="4">TOTAL FEES ENCLOSED = \$ 1,070.00</td> </tr> </tbody> </table>			Search Report has been prepared by the EPO or JPO	\$ 930.00	International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$ 720.00	No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 790.00	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 1070.00	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$ 98.00	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	[**] - 20 =		x \$22.00	Independent claims	[**] - 3 =		x \$82.00	Multiple dependent claims (if applicable)			+ \$270.00	TOTAL OF ABOVE CALCULATIONS = \$ 1,070.00				Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).				SUBTOTAL = \$ 1,070.00				Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				TOTAL NATIONAL FEE = \$ 1,070.00				Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				TOTAL FEES ENCLOSED = \$ 1,070.00			
Search Report has been prepared by the EPO or JPO	\$ 930.00																																																									
International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$ 720.00																																																									
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 790.00																																																									
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$ 1070.00																																																									
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$ 98.00																																																									
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																																																							
Total claims	[**] - 20 =		x \$22.00																																																							
Independent claims	[**] - 3 =		x \$82.00																																																							
Multiple dependent claims (if applicable)			+ \$270.00																																																							
TOTAL OF ABOVE CALCULATIONS = \$ 1,070.00																																																										
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed with this request (Note 37 CFR 1.9, 1.27, 1.28).																																																										
SUBTOTAL = \$ 1,070.00																																																										
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 OR <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).																																																										
TOTAL NATIONAL FEE = \$ 1,070.00																																																										
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.																																																										
TOTAL FEES ENCLOSED = \$ 1,070.00																																																										

			Amount to be refunded	\$
			charged	\$
a.	<input checked="" type="checkbox"/>	A check in the amount of \$1,340.00 to cover the above fees is enclosed.		
b.		Please charge my Deposit Account No. 03-2095 in the amount of \$ [**.**] to cover the above fees.		
c.	<input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. 03-2095. A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO:			 Signature Kristina Bieker-Brady, Ph.D. Reg No. 39,109	
Kristina Bieker-Brady, Ph.D. Clark & Elbing LLP 176 Federal Street Boston, MA 02110-2214 Telephone: 617-428-0200 Facsimile: 617-428-7045				

\Ceserver\documents\50062\50062.004001 US Nat'l Trans.wpd

DO NOT FILE THIS FORM

IN THE UNITED STATES PATENT AND TRADE MARK OFFICE

VERIFICATION OF TRANSLATION

I, Dr Lesley Margaret Stone, B.Sc., Ph.D., D.M.S., of Silver Creek, Lherry Cripperty, Union Mills, Isle of Man, IM4 4NJ, British Isles, do hereby declare that I am conversant with the English and French languages and that I am a competent translator thereof;

I verify that the attached English translation is a true and correct translation made by me of the attached document in the French language;

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment or both under Section 1001 of Title 18 of the United States code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 15th August, 1998

Lesley Stone
f

**AMINO ACID-ENRICHED PLANT PROTEIN RESERVES, IN
PARTICULAR LYSINE-ENRICHED MAIZE γ -ZEIN, AND PLANTS
EXPRESSING SUCH PROTEINS**

The present application relates to novel means enabling plants expressing 5 protein reserves which are enriched in amino acids and which are deficient in normal protein reserves to be prepared, in particular to lysine-enriched protein reserves. The invention also provides the thus modified protein reserves, and plants expressing these modified protein reserves.

Many plants, some after transformation using physico-chemical steps, are 10 of major economic importance for human or animal foodstuffs, and the problem of improving their nutritional quality has already given rise to different types of research. In particular, to overcome the insufficiency of certain amino acids in plant protein reserves, selected varieties have been developed which have superior nutritional qualities, or different modifications have been proposed which use 15 genetic engineering techniques to encourage or increase production in such plants of certain deficient amino acids which are nevertheless important for the nutritional qualities of the plant. Examples of deficient amino acids are lysine and methionine.

Within the context of the present application, the inventors have proposed 20 an original solution to the problem of improving plants, in particular improving their nutritional qualities, in the first instance using a plant of considerable economic importance, namely maize. More precisely, they have concentrated on the protein reserves in maize seed endosperm, which comprise zeins, in particular γ -zein.

As maize seeds develop, the cells of the endosperm synthesise large 25 quantities of protein reserves, in particular α -, β - and γ -zeins. Such zeins are accumulated in protein bodies derived from the endoplasmic reticulum (ER).

In general, zeins represent a complex protein group divided into a number 30 of groups, α -, β -, γ - and δ -zeins (Larkins et al., 1989) encoded by a multigenic family (Hagen and Rubenstein, 1980, Gene 13, 239-249). While their structure is variable, such proteins have common features: the presence of tandem repeats in

their primary structure which are rich in proline type amino acid residues, the presence of numerous hydrophobic residues which result in the insolubility of such proteins in aqueous media, and the absence of lysine residues, essential amino acids for man and for monogastric animals. The absence of lysine in all of the major 5 proteins (detected in large quantities in the endosperm) naturally produced in the zein group leads to an unbalanced amino acid composition in maize seeds.

Of such proteins, maize γ -zein is a protein with a molecular weight of 28 kDa, the coding sequence for which has been described in the cDNA form by Prat et al. (Nucleic Acids Research, vol. 13, n° 5, 1985, p 1494-1504). The complete 10 sequence of the gene coding for the γ -zein, including the upstream and downstream non coding sequences containing the expression regulation elements, has been described by M. Reina et al. (Nucleic Acids Research, vol. 18, n° 21, 1990, p 6426).

Up until now, different approaches have been envisaged for increasing the 15 amount of lysine in proteins of the zein group. In this respect, genetic and molecular approaches have been carried out. As an example, mutants for obtaining lysine-rich maize such as opaque-2 mutant (o2) and floury-2 mutant (fl-2) (Mertz et al., 1964, Science 145, 279-280, Nelson et al., 1965, Science 150, 1469-1470) have been proposed and attempts have been made to remedy the deleterious effects 20 of the absence of certain classes of zeins, in particular α -zeins, on the phenotype characteristics by selecting maize containing o2modifying genes (Paez et al., 1969, Plant Sci. 9, 251-252, Geetha et al., 1991, Plant Cell 3, 1207-1219).

Another approach has consisted in taking indirect action on the production 25 of free lysine, in particular in dicotyledonous plants. That technique involved deregulating key enzymes (DHTPS and AK) involved in the lysine via aspartate biosynthesis cycle. A cross sensitive to the levels of free lysine was obtained in the leaves, but not in the seeds, in tobacco plant transformation experiments with E. Coli bacteria containing dapA genes and E. Coli bacteria containing the lysC gene (Shaul and Galili, 1992, Plant J. 2, 203-209 and 1993, Plant Mol. Biol. 23, 759-30 768; Perl. A., Schaul O., Galili. G., 1992, Plant Molecular Biology 19, p 815-823).

Recently, the same genes, dapA from Corynebacterium and lysC from E. Coli, were used and expressed under the control of a specific promoter of seeds in soya plants. Expression of these two enzymes in soya led to a five times increase in the amount of lysine in the seeds (Falco et al., 1995, BIO-Technology 13, 577-582).

5 Other authors (Wallace et al., 1988, Science 240, 662-664) attempted to increase the lysine in α -zein (19 kDa) in maize seeds by point incorporation of lysine residues at different positions in the α -zein molecule. Expression of these constructs in Xenopus oocytes led to proper assembly of lysine-rich zeins in analogous vesicles of protein bodies. However, the normal α -zein and the lysine-enriched modified form were degraded when they were expressed in tobacco seeds
10 (Othani et al., 1991, Plant Mol. Biol., 16:117).

15 Thus there is currently no knowledge regarding the means which could enable expression of a lysine-enriched zein in cells producing it naturally in maize, i.e., in the endosperm cells. A fortiori, expression of lysine-enriched zeins in other plant cells has not been mastered.

One aim of the invention is thus to provide means for obtaining a lysine-enriched zein, in particular a lysine-enriched maize γ -zein, this protein being expressed particularly in maize seed cells and in particular in endosperm cells, said modified protein further being expressed such that its properties as regards localisation and accumulation in the endoplasmic reticulum and derivative protein bodies are preserved.
20

25 The expression "lysine-enriched" used in the present application means that the protein includes an increased number of lysine residues with respect to the natural protein from which it is derived, for example as a result of modifying the nucleotide sequence expressing it.

The invention also provides means for obtaining expression of proteins, preferably lysine-enriched γ -zeins, in plant cells of different tissues, for example leaf tissue or root tissue, and if necessary in the cells of plants which do not naturally express the protein, in particular the γ -zein the production of which is
30 desired.

In addition, in one particular implementation of the invention, other protein reserves can be enriched in lysine under analogous conditions.

In a first aspect, the inventors propose to introduce into the gene coding for the γ -zein or for other protein reserves of maize or other plants, or into the coding sequence of this gene, sequences coding for lysine-enriched polypeptides, in order to produce lysine-enriched γ -zeins or other proteins and thus to produce lysine-enriched seeds. Different sites in the coding sequence of the γ -zein gene have been identified as allowable sites (also known as neutral sites) to prepare the modified nucleotide sequences.

10 The present application thus proposes means for transforming the gene coding for the maize γ -zein or for transforming any nucleotide sequence coding for the γ -zein and derived from that gene, so as to obtain, by expression of the modified gene or, more generally, of the modified nucleotide sequence, a lysine-enriched protein; these means in particular include synthetic oligonucleotides 15 coding for an amino acid sequence comprising lysine residues.

The invention also provides recombinant nucleotide sequences or chimeral sequences which can code for a lysine-enriched γ -zein.

Still further, the invention provides host cells transformed by such sequences, in particular plant cells, for example cells enabling plant regeneration, 20 also plants or plant portions (tissues, organs...) containing such cells and producing modified protein reserves in a stable manner, in particular lysine-enriched γ -zeins.

The invention also encompasses said modified proteins, for example lysine-enriched proteins, and antibodies directed against these proteins.

25 An appropriate oligonucleotide for carrying out the invention for use in preparing recombinant nucleotide sequences is characterized in that it comprises at least one concatenation coding for a polypeptide with formula $(P-K)_n$, where:

- n is a whole number of 2 or more;
- P represents a proline amino acid residue;
- 30 • K represents a lysine amino acid residue;

- the symbol “-“ represents a bond between the two amino acid residues, in particular a peptide type bond, the n (P-K) units also being bonded together by such bonds, for example peptide type bonds.

5 In a first embodiment, an oligonucleotide of the invention is thus characterized in that it comprises a sequence coding for a series of repeated moieties comprising two amino acids.

The oligonucleotide codons may be identical for all of the proline and/or for all of the lysine residues. They may also be different for the same amino acid residue, the variation taking the degeneracy of the genetic code into account.

10 This oligonucleotide is preferably formed by a sequence coding for more than 2 (P-K) units. Preferably, n is 30 or less, in particular below 20 and advantageously, n equals 4, 5, 6, 7, 8, 9 or 10, or 15.

The “oligonucleotides” of the invention can be chemically synthesised using any available technique.

15 The term “polypeptide” referring to the concatenation (P-K)_n as used in the present invention means a sequence of amino acids containing more than 2 amino acid residues and which may comprise up to 60 amino acid residues.

20 In a first variation of the invention, the oligonucleotide comprises several concatenations coding for a polypeptide with formula (P-K)_n, identical or different, associated in tandem.

These oligonucleotides are either repeats of a single concatenation, or associations of different concatenations. The number of associated concatenations can vary, for example in the range 2 to 10 concatenations.

25 In a further variation of the invention, the oligonucleotide defined above is characterized in that it comprises at least one concatenation coding for a polypeptide with formula (P-K)_n, in which the sequence of n (P-K) units is interrupted by one or more amino acid residues other than P or K residues.

30 The supplemental amino acids incorporated into the sequence formed by the (P-K) units are preferably selected so as not to modify the organisation of the polypeptide coded by the oligonucleotide, or at the very least not to cause interaction with the amino acids of a protein into which said polypeptide would be

incorporated, under conditions which would affect the structure and/or function and/or localisation of this protein.

This can in particular be the case when the number of (P-K) units is high or when several concatenations formed from sequences coding for (P-K)_n moieties are 5 associated in tandem and when the preparation of the corresponding oligonucleotide requires that several nucleotide sequences be synthesised which are then associated by means of linkers, for example.

In a further embodiment of the invention, the oligonucleotide is such that the concatenation coding for the polypeptide comprising the n (P-K) units is 10 completed at its 5' end and/or at its 3' end by one or more codons coding, for example, for at least one lysine residue at the N-terminal extremity of the formed polypeptide.

As an example, a preferred oligonucleotide of the invention is characterized in that it codes for a polypeptide with formula (P-K), formula K-(P-K)₄, or with 15 formula 2K(P-K)₄.

In a particular embodiment, the composition of this oligonucleotide corresponds to one of the sequences described in the following pages and identified by designations SEQ ID No:1 and SEQ ID No:2.

The oligonucleotides described above constitute the basic resource for 20 producing recombinant nucleotide sequences capable of expressing lysine-enriched plant protein reserves or polypeptide reserves.

The invention thus provides a recombinant nucleotide sequence comprising a concatenation of nucleotides coding for a plant protein reserve, characterized in that it further comprises an oligonucleotide of the invention, inserted at one site of 25 the nucleotide concatenation selected such that:

- expression of the nucleotide sequence in a particular plant cell enables a modified protein reserve to be produced which is localised in that cell in a manner identical to or similar to the normal protein reserve which would be expressed in the same cell under the same conditions by the corresponding 30 normal coding nucleotide concatenation; and/or

- the modified protein reserve coded by the nucleotide sequence is immunologically recognised by antibodies produced against the corresponding normal protein reserve.

5 In particular, the antibodies cited above are constituted by a polyclonal serum or are obtained against epitopes of the normal protein reserve which are conserved in the modified protein reserve.

The plant cells referred to above include any plant cell, regardless of its tissue origin or its nature. Reserve organ cells are of particular interest within the context of the invention, but also the cells of leaves, stems, tubers....

10 The expression "protein reserve" of a plant as used in the present application means a protein synthesised during seed maturation and which is used during the germination phase as the principal food reserve.

15 In general, it concerns a polypeptide which can be synthesised in reserve tissue regardless of its location in the plant; in particular the protein reserves used in the present invention are those produced in the grain or seed of plants in the cereal, crucifer or legume group, and are, for example, prolamins or zeins.

20 The choice of the site(s) for inserting the oligonucleotide in the concatenation coding for the plant protein reserve is determined by satisfying the conditions described above. Depending on the case, insertion may take place in a repeat (in terms of amino acid sequence) of the protein or at the C- or N-terminal extremity.

25 The condition given above in which expression of the recombinant nucleotide sequence of the invention in a plant cell enables a modified protein reserve to be obtained, localised identically or similarly to the normal protein reserve which would be expressed under the same conditions in the same plant cell, comprising, for example for synthesised γ -zeins, the possibility of being accumulated in the endoplasmic reticulum of plant cells expressing it, in particular in the protein bodies formed from the endoplasmic reticulum, when the protein is expressed in endosperm cells.

In order to obtain this result by means of the recombinant nucleotide sequences of the invention, expression systems adapted to the cell host in which the selected nucleotide sequence is expressed, and in particular the regulation elements, for example, promoters, are selected for their functional character in the 5 tissue containing the transformed cells. Tests for making this selection can be carried out using the different constructs described in the examples.

To verify that the immunological properties of the modified protein reserve expressed by the nucleotide sequence of the invention have not been modified consequently, antiserums such as α G2 antiserum, described more precisely in the 10 experimental section below, have been used, for example.

In a first embodiment of the invention, the recombinant nucleotide sequence is characterized in that it is obtained from a nucleotide coding concatenation which leads to expression of a protein reserve which is naturally depleted in lysine.

In general, this recombinant nucleotide sequence codes for a modified 15 protein reserve derived from a protein reserve which is naturally produced by a plant for use in animal or human foodstuffs.

Thus protein reserves in which the lysine content has been modified within the context of the present invention are advantageously plant protein reserves from the cereal, legume or crucifer group. Particularly important protein reserves are 20 those in maize, in particular zeins, and more particularly maize γ -zein, for which the lysine content is intended to be increased.

One particular recombinant nucleotide sequence of the invention is characterized in that the coding concatenation of nucleotides coding for the maize γ -zein which it contains has the sequence shown in Figure 9.

25 Other recombinant nucleotide sequences of the invention are characterized in that the coding concatenation of nucleotides they comprise codes for a protein reserve of a plant selected from the following: soya, sunflower, tobacco, wheat, oats, alfalfa, rice, oilseed rape, sorghum, and Arabidopsis.

In a preferred embodiment of the invention, in the recombinant nucleotide 30 sequence comprising a concatenation coding for maize γ -zein, the oligonucleotide

of the invention is inserted in place of the concatenation coding for the Pro-X domain naturally present in the maize γ -zein amino acid sequence or following this concatenation. The Pro-X domain of the maize γ -zein amino acid sequence is constituted by the amino acids located between positions 70 and 91 of the amino acid sequence shown in Figure 9, corresponding to nucleotides 265 to 330 of the sequence shown in Figure 9.

Preferably, in the nucleotide sequence of the invention, the oligonucleotide in place of or following the Pro-X domain is present between nucleotides 276 and 357 of the sequence shown in Figure 9.

In a further embodiment of the invention, in the recombinant nucleotide sequence comprising a concatenation coding for maize γ -zein, the oligonucleotide of the invention is inserted following the Pro-X domain conserved in the maize γ -zein sequence.

In a further variation, in the recombinant nucleotide sequence comprising a concatenation coding for maize γ -zein, the oligonucleotide of the invention is inserted into the Pro-X domain maintained in the γ -zein sequence.

The above insertions can be carried out using available techniques, for example recombination of sequences which have undergone one or more enzymatic digestion steps.

In a particular embodiment of the invention, a selected protein reserve enriched in a particular amino acid is expressed in heterologous plant cells. In other words, a protein reserve which is naturally present in a given plant is expressed in an amino acid-enriched form in another plant or in a cell other than that in which it is naturally produced.

In addition to the concatenation coding for a plant protein reserve and the oligonucleotide of the invention, the recombinant nucleotide sequences of the invention can also comprise an expression promoter, for example a promoter selected for its specific expression character in certain parts or tissues of the plants, or in contrast a promoter selected for its constitutive character. As an example, when they are specific, the promoters can be specific for seeds and/or organs or particular plant tissues. They

can alternatively, or also, be specific for one growth phase, for example a particular stage of germination.

In contrast, the use of constitutive promoters means expression of the protein reserve is constant and general, causing competition between expression of 5 the native protein reserve, when it is present, and the modified protein reserve.

As an example, advantageous promoters for carrying out the invention are the maize γ -zein promoter contained in the 1.7 kb sequence found upstream of the coding sequence shown in Figure 7, the cauliflower mosaic virus promoter, namely the promoter CaMV35S (European patent EP-B-0 131 623), the constitutive 10 promoter for the actin 1 rice gene (PCT application PCT/US 9100073) or the specific "high molecular weight glutathione" seed promoter for wheat (Colot V. et al., 1987, EMBO Journal, vol. 6, p 3559-3564).

If necessary, these promoters are completed by other regulation sequences, in particular expression activators.

15 Examples of other promoters which can be used in carrying out the invention are the promoter for the gene coding for the 2S protein reserve in Arabidopsis thaliana, or the lectin or β -phaseoline promoters for beans.

Supplemental introduction of expression activators into the regulation 20 sequences of the nucleotide sequences of the invention can also increase the level of primary transcription of the nucleotide sequence and, if appropriate, increase the quantity of modified protein reserves produced. The activators are, for example, introns of monocotyledons such as intron 1 of the rice actin gene.

The invention also provides a cloning and/or expression vector, characterized in that it comprises, at a site which is not essential for replication, a 25 nucleotide sequence satisfying one of the definitions given above. Examples of vectors of particular interest within the context of the present invention are the plasmids pP20 γ Z, pH30 γ Z or pH45 γ Z. Plasmid pP20 γ Z was deposited at CNCM [National Collection of Micro-organism Cultures] (Paris, France) on 31st October 1995, registration number I-1640. Plasmid pH45 γ Z was deposited at the CNCM 30 on 31st October 1995, registration number I-1639.

The scope of the invention also encompasses a polypeptide as expressed by a recombinant nucleotide sequence satisfying the above definitions.

The expression "polypeptide" as used within the context of the invention does not introduce a particular limitation as regards the number of amino acids forming the polypeptide. It may include sequences comprising several amino acids, normally termed peptides, or much longer sequences such as those in proteins.

In this regard, the invention provides lysine-rich modified maize γ -zein, characterized in that it is coded by a recombinant nucleotide sequence as described above.

10 In a preferred embodiment of the invention, the lysine-enriched modified maize γ -zein is characterized in that its amino acid sequence is modified by at least one polypeptide with formula $(P-K)_n$, where:

- n is a whole number of 2 or more;
- P represents a proline amino acid residue;
- 15 • K represents a lysine amino acid residue;
- the symbol “-“ represents a bond between the two amino acid residues, in particular a peptide type bond, the n $(P-K)$ units being bonded together by such bonds, in particular peptide type bonds.

20 In a variation, the polypeptide integrated in the γ -zein amino acid sequence has the formula $K-(P-K)_n$.

The polypeptides of the invention with one of formulae $(P-K)_n$, $K-(P-K)_n$ or with one of the variations are substituted for a sequence naturally present in the normal maize γ -zein or inserted with deletion of one or more amino acids of the amino acid sequence of normal maize γ -zein, or added to the normal γ -zein amino acid sequence, the insertion site for the polypeptide being selected such that:

- when the modified lysine-rich γ -zein is produced in a host cell, in particular in a plant cell, it is localised in that cell in identical or similar manner to normal maize γ -zein which would be produced under the same conditions, in the same host cell; and/or

- the modified maize γ -zein is recognised by antibodies directed against the normal maize γ -zein.

The P20 γ Z proteins shown in Figure 11 or H30 γ Z or H45 γ Z shown in Figure 10 are preferred embodiments of the invention and represent lysine-enriched 5 modified maize γ -zeins.

The invention also provides a recombinant host cell, characterized in that it comprises a nucleotide sequence as described above.

Examples of host cells of interest are bacterial cells, such as *E. Coli* or *Agrobacterium tumefaciens*. Preferably, within the context of the invention and for 10 stable expression of the desired modified protein reserve, host cells of plant origin will be used.

As an example, the cells of plant origin are seed, plant and, for example, as is preferred, maize seed endosperm cells.

The nucleotide sequence of the invention is preferably introduced into the 15 genome of the host cell in a stable manner and under conditions such that the expressed protein reserve which is enriched in amino acids, in particular lysine, is localised as the corresponding normal protein would be in the same host cell.

A variety of techniques are available for transforming host cells. Examples for transforming host cells in a stable or transient manner, electroporation, 20 bombarding with microprojectiles carrying DNA using a particle cannon, explant culture with *Agrobacterium tumefaciens*, by microfibre penetration.

In addition to maize seed endosperm cells, soya, sunflower, tobacco, wheat, oats, alfalfa, rice, oilseed rape, sorghum or *Arabidopsis* cells can be used to express the nucleotide sequences of the invention.

25 The present application also relates to seeds producing a polypeptide as described above and the plants producing this polypeptide. These plants are preferably maize.

The invention also relates to seeds obtained from transformed plants expressing the polypeptide of the invention, in other words the modified protein 30 reserve enriched with particular amino acids.

In a particularly interesting embodiment of the invention, the modified lysine-enriched γ -zein proteins are expressed in opaque-2 maize mutants. The lysine content of these o2 mutants described by Emerson R. A. et al., (1935, Cornell Univ. Agric. Exp. Stn. Mem. 180) and characterized by Mertz E. T. et al., 5 (1964, Science 145: 279-280) is substantially increased thus greatly increasing the nutritional qualities of the maize (compensating for the its low level of this essential amino acid). Conventional maizes have a lysine content of about 0.24% of the raw product (total grain weight), but opaque-2 maizes have close to 0.5% of lysine. However, they have insufficient agronomic characteristics as their endosperm is far 10 less vitreous and is very friable ("starchy" phenotype). This renders them extremely sensitive to pathogenic organisms and to post harvest treatments. This phenotype is due to a large reduction in certain protein reserves, in particular alpha zeins. In fact, opaque-2 codes for a transcription factor necessary for expression of certain zein genes (Schmidt R. J. et al., 1990, Proc. Natl. Acad. Sci. USA, 87, 15 46-50).

Opaque-2 derivatives no longer having the disadvantages cited above have been developed by conventional genetic improvement, namely QPM (Quality Protein Maize). Recent genetic analysis of these maizes (Lopes M. A., et al., 1995, Theor. Appl. Genet. 19, 274-281) has shown that only 2 or 3 loci are key 20 loci in these favourable modifications. More detailed genetic and biochemical analyses have resulted in the postulation that one of the 3 loci responsible is the γ -zein locus: maize genotypes which carry a duplicate of this gene located in the centrometric region of chromosome 7 have all been shown to be opaque-2 modifiers (Lopes M. A. et al., 1995, Mol. Gen. Genet. 19: 247: 603-613).

25 The present invention also enables opaque-2 mutant maizes to be prepared from maize having only one γ -zein gene in chromosome 7, which are complemented by addition of a recombinant sequence coding for a lysine-enriched maize γ -zein. In addition to acquiring hardness properties similar to a non mutant opaque-2 maize, it has the advantage of significantly increasing the lysine content, 30 thus exceeding that of QPM maize.

The present invention enables modified maize opaque-2 mutants to be obtained, into which a recombinant nucleotide sequence coding for a lysine-enriched maize γ -zein has been inserted.

5 The invention also provides a method of obtaining plants or seeds expressing a modified protein reserve, characterized in that it comprises the steps of:

- a) transforming a plant cell, with a nucleotide sequence or a vector as described above, under conditions enabling the modified protein reserve coded by the nucleotide sequence to be expressed in a stable and functional manner;
- 10 b) regenerating plants from the plant cell transformed in step a), to obtain plants expressing the modified protein reserve;
- c) if necessary, obtaining seeds from the modified plants obtained in step b).

In an advantageous implementation of the invention, the transformed plant is maize and the enriched modified protein reserve is lysine-enriched γ -zein.

15 The invention also relates to plants obtained by carrying out such a method.

In order to evaluate the content of a given amino acid in plants of the invention, it is possible to use an assay protocol such as that described in Zarkadas et al., 1995, J. Agri. Food Chem. Vol. 43: pages 84-93.

20 Further characteristics and advantages of the invention will become apparent from the following examples and the accompanying figures.

Figure 1

- Restriction map of plasmid pP20 γ Z;

Figure 2

- Restriction map of plasmid pH45 γ Z;

25 **Figure 3**

- Schematic representation of proteins coded by modified and non modified γ -zein genes: wild type γ -zein (γ Z), and lysine-rich γ -zeins (P20 γ Z, H30 γ Z, H45 γ Z and N13 γ Z) resulting from inserting oligonucleotides coding for lysine-rich sequences. The amino acid sequence of the inserted polypeptides is indicated

using the single-letter amino acid designations. The following abbreviations are used:

Term: terminal;

ProX DOMAIN: proline-Xaa linker domain.

5 **Figure 4** - In-vitro analysis of lysine-rich γ -zeins. (A) in vitro translation and translocation of transcripts corresponding to lysine-rich modified γ -zeins; lines 1, 5, 9 and 13: complete translation products; lines 2, 6, 10 and 14: complete translation products after translocation in canine microsomes (CM); lines 3, 7, 11 and 15: translocation products resistant to the action of proteinase K (PK); lines 4, 8, 12
10 and 16: totality of translation products after treatment with proteinase K in the presence of 0.5% Nonidet P40 (NP40). (B) Immunoprecipitation of in vitro translation products corresponding to γ -zein proteins and lysine-rich modified γ -zein, using α PL antiserum. Line 1: γ -zein; line 2: P20 γ Z; line 3: H30 γ Z; line 4: H45 γ Z and line 5: N13 γ Z. (C) Same legend as for (B) but using α G2 antiserum.
15 The molecular weight markers (in kilodaltons) are shown on the left.

20 **Figure 5** - Tissue-specific activity of the γ -zein promoter. Maize endosperms, embryos and leaves were transformed by bombarding with particles using the constructs represented in the figure (in the right hand portion). The relative activities of luciferase (LUC, grey columns) and β -glucuronidase (GUS, hatched columns) are expressed in the form of a multiplier of the values obtained with naked projectiles \pm the standard deviation of the different ratios.

25 **Figure 6** - Expression of lysine-rich γ -zeins in the sub-aleuronic endosperm of cells. (A) Immunoblot with α PL antiserum, of proteins extracted from endosperms transformed by pN13 γ Z (line 2), pH45 γ Z (line 3), pH30 γ Z (line 4) and pP20 γ Z (line 5). The control (line 1) corresponds to non transformed endosperms. The molecular weight markers (in kilodaltons) are shown on the left hand side. (B)
30 Expression of transcripts H45 γ Z and N13 γ Z in transiently transformed endosperms. The cDNAs obtained from tissues transformed with pH45 γ Z (line 2), pN13 γ Z (line 3) and the control (line 1) were amplified by PCR and analysed using a synthetic oligonucleotide coding for a lysine-rich sequence used as a probe.

Figure 7 - Accumulation of lysine-rich γ -zeins in the protein bodies of the endosperm. (A) Immunoblot analysis, using α PL antiserum, of protein bodies isolated from endosperms transformed with pP20 γ Z (line 1), pH30 γ Z (line 2), pH45 γ Z (line 3), pN13 γ Z (line 4) and no DNA (line 5). (B) Immunoblot analysis, using α PL antiserum, of protein bodies isolated from endosperms transformed with pP20 γ Z, pH30 γ Z and pH45 γ Z and digested with proteinase K in the presence of an isotonic buffer (Sugar., lines 1, 3 and 5) or a hypotonic buffer (H_2O , lines 2, 4 and 6). The molecular weight markers (in kilodaltons) are shown on the left hand side.

Figure 8 - Co-localisation of P20 γ Z proteins with α - and γ -zeins in protein bodies of maize endosperm. An immunocytochemical analysis was carried out on ultrafine sections using α PL antibodies (labelled with 15 nm diameter gold particles) and α Z and α G2 antibodies (labelled with 5 nm particles). (A) protein bodies of endosperm transformed with pP20 γ Z, immunolabelled with α PL antibody. (B) Immunolocalisation of P20 γ Z (labelled with 15 nm gold particles) and γ -zein (labelled with 5 nm gold particles) in protein bodies isolated from endosperms transformed with pP20 γ Z. (C) and (D) Immunolocalisation of P20 γ Z (labelled with 15 nm gold particles) and γ -zeins (labelled with 5 nm gold particles) in protein bodies isolated from endosperms transformed with pP20 γ Z. The arrows indicate tangential sections of the protein bodies.

Figure 9 - Coding sequence of maize γ -zein cDNA and the corresponding amino acid sequence.

Figure 10 - Coding sequence of cDNA of the H45 γ Z maize zein and the corresponding amino acid sequence.

The lysine-rich sequence (28 amino acids) was introduced between amino acid residues 92 and 119 of the sequence shown in Figure 10.

Figure 11 - Coding sequence of cDNA of the P20 γ Z maize zein and the corresponding amino acid sequence.

The lysine-rich sequence (14 amino acids) was introduced between amino acid residues 92 and 119 of the sequence shown in Figure 11.

Figure 12 - Restriction maps for plasmids Pbin 19P20 γ Z and pBin19H30 γ Z.

Figure 13 - Transgenic maize plant endosperms accumulating lysine-enriched γ -zein.

A and B: SDS-page and immunoblot using α PL antiserum.

5 A) 10 μ g of protein per track (transformants with construct H45 γ Z)
 track C: protein extract from endosperms of hybrids B73xA188 (control)
 track 1: A1
 track 2: B1
 track 3: B2
 10 track 4: C1
 track 5: D1
 track 6: D2

B) 1 μ g of protein per track (transformants with construct P20 γ Z)

15 track C: control
 track 1: A1
 track 2: A2
 track 3: B1
 track 4: C1
 20 track 5: D1
 track 6: E1

C) SDS-PAGE and stain with silver (3 P20 γ Z transformants and 3 H45 γ Z transformants)

25 track 1: A2]
 track 2: B1]
 track 3: C1] 10 μ g of protein per track
 track 4: B1]
 track 5: A1]
 30 track 6: D2]

track 7: B1]
 track 8: A1] 40 μ g of protein per track
 track 9: D2]

35

Figure 14 - Lysine-enriched γ -zein content per grain (transformants 45 γ Z B1 and C1)

A: silver stain; 10 µg of protein per track;

B immunoblot using α PL antiserum; 1 µg of protein per track;

Tracks 1 to 5: protein extracts from different endosperms of transformant 45 γ Z B1;

5 Tracks 6 to 10: protein extracts of different endosperms of transformant 45 γ Z C1.

Figure 15:

A) Lysine-enriched γ -zein content of 10 grains (transformant 45 γ Z C1) using α PL antiserum, 1 µg of protein per track;

Tracks 1 to 10: endosperm extract from 10 descendants;

10 B) Immunoblot of protein extracts of endosperms 1 to 5 present in A) and labelled with α G2 antiserum; 2 µg of protein per track.

EXAMPLES

15 **A) Preparation of lysine-enriched modified γ -zeins and expression of these modified proteins followed by accumulation in protein bodies of maize endosperm cells**

γ -zein is a sulphur-rich maize protein reserve, with a molecular weight of 28 kD which is accumulated in endosperm cells with α - and β -zeins, in protein bodies derived from the endoplasmic reticulum (ER) of the grain (Ludevid et al., 1984, Plant Mol. Biol. 3, 227-234; Lending et al., 1984, Plant Cell 1, 1011-1023). The amino acid sequence deduced from the cDNA nucleotide sequence (Prat et al., 1985, Nucl. Acids Res. 13, 1493-1504) and genomic clones (Boronat et al., 1986, Plant Sci. 47, 95-102) show that the γ -zein has no homology with α -zein type polypeptides. While the γ -zein is coded by 1 or 2 genes per haploid genome (Boronat et al., 1986, Plant Sci., 47, 95-102), it represents 10-15% of the totality of the maize endosperm proteins. Expression of the γ -zein gene in heterologous systems such as *Xenopus* oocytes (Torrent et al., 1994, Planta 192, 512-518) and in *Arabidopsis thaliana* (Geli et al., 1994, Plant Cell 6, 1911-1922), indicates that γ -zein polypeptides remain stable and are capable as they are of forming protein bodies derived from the endoplasmic reticulum inside the cells. Further, analyses

involving deletion of different structural domains from the γ -zein have shown that the N-terminal sequence including the proline-rich repeat is responsible for retaining the γ -zein in the endoplasmic reticulum and the cysteine-rich C-terminal domain is responsible for forming the protein bodies. The Pro-X domain does not 5 appear to affect the stability of the protein nor its targeted localisation (Geli et al., 1994, *Plant Cell* 6, 1911-1922).

Material and methods

Plant material

10 After surface sterilisation (1), grains at stage 17 DAP (days after pollination) of W64A maize were dissected by hand and the pericarpal layer and the aleurone were separated from the endosperms. Tangential sections were made to expose a large part of the sub-aleuronic surface. If necessary, embryos were isolated and leaves from 7 day old plants were dissected to extract the epidermal tissue. After dissection, the samples were placed in petri dishes on filter paper 15 moistened with MS medium (Murashige and Skoog, 1962, *Physiol. Plant* 15, 473-497).

Plasmid constructs

20 A first group of plasmids, pKSG2, pHbP2, pPbP4 and pNaN1, was obtained to enable restriction sites to be introduced into the gene coding for γ -zein. pKSG2 and pHbP2 were constructed in accordance with the description in the publication by Torrent et al. (*Planta* (1994) 192: 512-518). Plasmid pKSG2 contained the sequence coding for γ -zein.

25 Plasmid pHbP2 was obtained from pKSG2 and contained a sequence coding for a mutated γ -zein from which the Pro-X domain of the protein had been deleted.

30 Plasmid pPbP4 was obtained following two cloning steps: (i) the restriction fragment Sall-Pvull of 350 kb from pKSG2 was cloned in a Bluescript plasmid (pBSKS, Stratagen, La Jolla, California, USA) restricted with Sall and EcoRV (pKSC4) and (ii) the restriction fragment Pvull-XbaI of 600 bp from pKSG2 was cloned in restriction sites SmaI-XbaI of pKSC4. The new construct pPbP4

contained a useful EcoRI restriction site just before the P-X domain of the γ -zein coding sequence.

Plasmid pNaN1 was also obtained following two cloning steps. (i) the Nael-XbaI fragment of 250 bp from pKSG2 was cloned in the plasmid pBSKS 5 restricted with EcoRV-XbaI (pKSC8) and (ii) the restriction fragment Nael-HindIII of 700 bp (open ends) from pKSG2 was cloned in the HindIII restriction site of pKSC8. The new construct, pNaN1, contained restriction sites Clal and HindIII at a position located 15 nucleotides in front of the stop codon for the γ -zein.

Two synthetic nucleotides with the following sequences: SEQ ID N° 1:
10 5'CGATGAATTCAAACCAAAGCCAAAGCCGAAGCCAAAAGAATTCA3',
and the inverse sequence termed SEQ ID N° 2, with the following sequence:
5'AGCTTGAATTCTTTGGCTTCGGCTTGGCTTGGTTGAATTCA3'
coding for lysine-rich sequences termed (P-K)₄, were hybridised, digested with EcoRI and cloned in a EcoRI site of pHbP2 and pPbP4. Three clones were
15 selected: pPo2 and pHo3 containing the sequence coding for K(P-K)₄ and pHo4 comprising the truncated form of the sequence coding for γ -zein containing a tandem 2K(P-K)₄ (in the form of a sequence K(P-K)₄ EF K(P-K)₄) of the lysine-rich coding sequence. The same hybridised oligonucleotides were digested with Clal-HindIII enzymes and cloned in plasmid pNaN1 restricted using the same enzymes.
20 The selected clone, pNo1, contained the sequence coding for the lysine-rich sequence K(P-K)₄ at the N-terminal extremity of the corresponding modified γ -zein.

For transient transformation of the endosperm, sequences coding for the modified γ -zein of pPo2 and pHo3 were inserted in the form of HincII-NheI 25 fragments in SmaI-XbaI sites of pDH51 (Pietrzah et al., 1986, Nucl. Acid Res., 14, 5857-5868) containing the 35S promoter of the cauliflower mosaic virus (CaMV). The promoter pP20 γ Z obtained by the insertion described above of HincII-NheI fragments in plasmid pDH51 contained the coding sequence for lysine-enriched γ -zein (Figure 8) and signals of the 35S sequence of the CaMV virus for forming the 30 3' end and polyadenylation. The chimeral coding sequence P20 γ Z was constructed

from the region coding for γ -zein contained in the pKSG2 plasmid after different cloning steps. The 1.7 kb promoter for the γ -zein (Reina et al., 1990, Nucl. Acids Res. 18, 6426) was inserted in the blunt ends of a HindII-Pvul fragment in pH04 and pNo1 restricted with Xh01 and obtained with blunt ends. Constructs pH45 γ Z and pN13 γ Z were obtained respectively.

The novel constructs, respectively termed pP20 γ Z, pH30 γ Z, pH45 γ Z and pN13 γ Z, were used in biolistic bombardment experiments.

To study the specificity of different promoters as regards plant tissues, two constructs, p1.7 γ ZGUS and pCaMV35SLUC were used. p1.7 γ ZGUS was obtained by inserting the 1.7 kb γ -zein promoter (HindIII-Pvul) into a plasmid derived from pPuC18 containing the GUS gene and NOS signals for polyadenylation of pBI 101.1 at 3' (Jefferson et al., 1987, Embo. J. 6, 3901-3907). pCaMV35SLUC was obtained by inserting the gene coding for luciferase (LUC) from pAHC18 (Bruce et al., 1989, P. H. 86, 9692-9696) into the pDH51 polylinker (Pietrzak et a., 1986, Nucl. Acids Res. 18, 6426).

In-vitro analysis

The plasmids derived from pBSKS containing the coding sequences for the γ -zein (pKSG2) and lysine-rich γ -zein (pPo2, pHo3, pHo4 and pNo1) were transcribed in vitro using standard protocols (Sambrook et al., Molecular Cloning: A laboratory manual, 2nd edition, Cold Spring Harbor Laboratory ed., Cold Spring Harbor, New York). In vitro translation and translocation of the synthetic transcripts was carried out using the Torrent et al technique (1994, Planta 192, 512-518), with the exception of the canine microsomes (CM) which originated from Promega (Madison, Wis., USA). The translated products were immunoprecipitated essentially using the Borgese and Gaetani method (1980) using an anti- γ -zein α -G2 rabbit serum (Ludevid et al., 1985, Plant Sci., 41, 41-48) and an α PL antiserum. α PL is a polyclonal rabbit antiserum obtained against the synthetic peptide EFK(P-K)₈EF. This peptide was synthesised using the solid phase synthesis technique described by Celma et al., 1992.

Plasmidic DNA was absorbed onto gold particles (1.0 μ m, Bio-Rad, Lab., Richmond, CA, USA) using a protocol described by Kikkert (Plant Cell, 33: 221-226, 1993). All of the targets were bombarded twice, using a BioRad Biolistic PDS/100/He apparatus. The targets were positioned 8 cm behind a screen 5 stopping macrocarriers, which were positioned 1 cm below a 900 PSI rupture disk. After bombardment, the samples were incubated for 24 hours at 26°C in the dark. The controls were constituted by targets bombarded with microprojectiles containing no DNA.

Enzymatic tests

10 Tissues bombarded with p1.7 γ ZGUS and pCaMV35SLUC plasmids were homogenised over ice in a buffer containing 25 mM of Tris, at a pH of 7.8, 2 mM of DTT, 10% of glycerol and 1% of Triton X-100. After centrifugation at 12000 g for 5 minutes, the supernatants were decanted and the total soluble protein in the extracts was quantified using the Bradford test (Bio-Rad). The GUS activity was 15 tested by fluorimetric analysis following the description by Jefferson (1987) using 4-methyl-ombelliferyl- β -D-glucuronide (MUG) as a substrate. The LUC activity was determined using a Luciferase Assay System Kit sold by Promega, following the manufacturer's instructions.

Extraction of protein reserves and gel analysis of proteins

20 Endosperms transformed with pP20 γ Z, pH20 γ Z, pH45 γ Z and pN13 γ Z were reduced to flour and the α -zeins were extracted by means of three series of solvents containing 70% of ethanol. The residual flour was air dried, and the total proteins were extracted with a buffer containing 0.25 M of Tris-HCl, pH 6.8, 4% of sodium dodecyl sulphate (SDS) and 5% of 2-mercaptoethanol, for 1 hour at 25 ambient temperature. The protein extracts were analysed by SDS-PAGE and immunoblot following the description by Ludevid et al., 1985. Nitrocellulose leaves were incubated with α PL antiserum (dilution 1:500) and Raifort peroxidase conjugated with a secondary antibody (ECL Western Blotting System, Amersham, Buckinghamshire, UK) was used to detect the protein.

Total RNA was extracted in accordance with the description by Logemans et al., 1987. Complementary DNA (cDNA) was prepared using reverse transcriptase and oligo dT from Gibco BRL (Gaithersburg, MD, USA) following the manufacturer's instructions, and this RNA was amplified using a PCR reaction.

5 Primer oligonucleotides used for the PCR were 20-mer sequences corresponding to the 5' and 3' ends of the γ -zein structure. Standard protocols were used to prepare the 32 P labelled probes, and for gel analysis of the DNA (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Ed., Cold Spring Harbor, New York) using a synthetic oligonucleotide coding for

10 a lysine-rich sequence (see above) as a probe.

Isolation of protein bodies and treatment with protease

These protocols were described above (Torrent et al., Planta, 180: 90-95, 1989).

Electron microscopy

15 The protein bodies of wild type endosperms and endosperms transformed by pP20 γ Z were fixed with 2.5% of paraformaldehyde in 20 mM of phosphate buffer at pH 7.2, for 1 hour at ambient temperature, and transformed in accordance with the description by Geli et al., 1994, Plant Cell 6, 1911-1922), using, however, a α PL antiserum and a colloid of gold and protein A with a diameter of 15 nm.

20 For double labelling, ultra fine sections were first incubated with α PL and the colloid of gold and protein A (15 nm diameter) was used to detect the antibody. After washing, sections were incubated with 0.15 mg/ml of protein A for 20 minutes to saturate the immunoglobulins and finally the screens were incubated with α -G2 or α -Z1 sera and the gold/protein A colloid (5 nm diameter) was used

25 to detect the antibody. α -Z1 is a polyclonal rabbit antiserum directed against the α -zein obtained following the description by Ludevid et al., 1985, Plant Sci., 41, 41-48.

Results

Construct of lysine-rich γ -zeins

The inventors have demonstrated the importance of the proline-rich repeat and the cysteine-rich C-terminal domain for retention of the γ -zein in the 5 endoplasmic reticulum and the formation of protein bodies containing these proteins in the cells of Arabidopsis leaves (Geli et al., 1994, Plant Cell 6, 1911-1922). On the basis of these previous results, the possibility of inserting lysine-rich sequences in different domains of the γ -zein, to create a modified γ -zein correctly targeted and accumulated in the endosperm cells, was investigated to improve the 10 nutritional qualities of the maize.

The inventors have now constructed modified γ -zein genes by introducing synthetic oligonucleotides coding for lysine-rich sequences into different sites of the γ -zein coding sequence. Modified γ -zein constructs were created so as to avoid placing lysine-rich coding sequences in domains constituted by the tandem 15 repeat and the cysteine-rich domain. Modifications of the γ -zein coding sequence were made in the sequence corresponding to the Pro-X domain. Further, to minimise any alteration to protein folding, the lysine-rich sequences (P-K)_n were defined to imitate the sequence of the Pro-X domain. As can be seen in Figure 3, a sequence K(P-K)₄ has been introduced into the protein P20 γ Z after the Pro-X 20 region and in protein H30 γ Z and in protein H45 γ Z, amino acid sequences including K(P-K)₄ and 2K(P-K)₄ respectively replace the Pro-X domain of the γ -zein (γ Z, fig, 3). To study whether the C-terminal extremity was a neutral site for the introduction of lysine-rich sequences, a supplemental N13 γ Z protein was created by inserting a sequence containing K(P-K)₄ five amino acids upstream of the C- 25 terminal extremity (Figure 3).

Activity of the γ -zein promoter in transformed maize endosperm

To determine whether lysine-rich γ -zeins could be expressed in endosperm cells, an efficient promoter and a transformation system were researched in the first instance. A γ -zein promoter containing an upstream 1.7 kb sequence (Reina et al., 30 1990, Nucleic Acid Research, vol. 18, p 6426) and the CaMV promoter containing

625 bp of the sequence upstream of the 35S protein of the cauliflower mosaic virus CaMV were tested. Until now, no information has been available on the functional analysis of gene fusions with the γ -zein promoter in transgenic monocotyledonous plants. To analyse the activity and tissue specificity of the γ -zein promoter, two 5 chimeral genes were constructed (see Figure 5). Transient expression by biolistic bombardment (Klein et al., 1988 PNAS 85: 4305) was used as the maize transformation procedure to analyse the promoter and for lysine-rich γ -zein expression experiments. Maize endosperms at the 17 DAP (days after pollination) stage (the pericarp and the cells of the aleuronic layer were removed), embryos (17 10 DAP) and young leaves (10 days old) were bombarded with gold projectiles coated with plasmidic DNA containing the two constructs. Figure 5 shows the β -glucuronidase (GUS) activities and luciferase (LUC) activities present in the three tissues tested: endosperm, embryo and leaf, with respect to the control experiment. It should be noted that the results correspond to the average of at least 3 15 independent experiments carried out. All GUC activity under the control of the γ -zein promoter was restricted to the endosperm, since no GUS expression was detected in the embryo and in the leaves. Further, the bombarded endosperms were histochemically stained to determine the number of cell clusters expressing the GUS protein. The stain profile corroborated the above results, GUS being 20 strongly expressed in the endosperms (the average number of GUS stained clusters per endosperm was 150) and blue spots were not detected in the embryo and in the leaves. In contrast, the promoter CaMV35S conferred a LUC activity on all of the tissues tested (Figure 5), but there were quantitative differences between the relative activity of the enzyme in the leaves and the embryos with respect to the 25 endosperm. These differences could be attributed to an intrinsic variability in the constitutive activity of the CaMV promoter between the different maize tissues or to low penetration of DNA-coated particles into the mesophyll cells containing a large vesicular system. The prior art contains tests in which the CaMV promoter normally has low activity in monocotyledonous plant cells (Fromm et al., 1985, 30 Proc. Natl. Acad. Sci. USA 82, 5824-5828); however, the inventors have

demonstrated a high activity of the CaMV promoter in endosperm cells. This prompts the conclusion that the activity of the γ -zein promoter and the CaMV35S promoter was very high in maize endosperms and thus the two promoters could be useful in controlling expression of the protein in this tissue.

5 In order to determine if the mutant proteins coded by the constructs were competent with the membrane translocation function, in-vitro transcription-translation experiments were carried out in the presence of dog pancreatic microsomes. The synthetic transcripts of each construct were translated and translocation through the microsome membranes was tested by examining the 10 protection as regards the digestion with K proteinase. These results, shown in Figure 4A, indicate that the apparent molecular weights of in-vitro synthesised polypeptides reflect the mutations introduced (Figure 4A, lines 1, 5, 9 and 13). In the presence of microsomes and the K proteinase, low molecular weight peptides were not observed, indicating that the complete polypeptide chains of the modified 15 γ -zeins were transported through the microsomal membranes (Figure 4A, lines 3, 7, 11 and 15). By comparing the result of translocation of the four modified γ -zeins, it can be seen that protein H45 γ Z (Figure 4A, line 11), which contained the 10 lysine type amino acid insertion, had undergone less translocation than the other proteins. It appears that negatively charged residues could interfere to a certain 20 extent with translocation efficiency. Since the polyclonal antibody α G2, directed against γ -zein (Ludevid et al., 1985, Plant Sci. 41, 41-48) could not be used to distinguish between the wild type γ -zein and modified γ -zeins, an α PL antibody directed against a synthetic peptide containing the lysine-rich amino acid sequence 25 was prepared. It was then tested to examine whether the modified proteins synthesised in vitro were recognised both by the α G2 antibodies and the α PL antibodies. This experiment is illustrated in Figure 4B and Figure 4C where the synthetic transcripts of the γ -zein, P20 γ Z, H30 γ Z, H45 γ Z and N13 γ Z, were translated in-vitro and in which the translation products were immunoprecipitated with α PL (Figure 4B) and with α G2 (figure 4C). These results indicate that 30 lysine-rich γ -zeins were recognised by the two antibodies (see Figure 4B and C,

lines 2 to 5) and that the γ -zein was only recognised by the α G2 serum (Figure 4B and C, line 1). Thus the specificity of the antibodies α PL for the modified proteins enabled the lysine-rich γ -zein to be distinguished from the endogenic γ -zein when the modified genes were expressed in endosperm cells. Taken together, these 5 experiments have shown that the presence of lysine-rich sequences did not disturb the function of translocation through the membrane or the immunological behaviour of the γ -zein.

Analysis of expression of lysine-enriched γ -zeins in maize endosperms

To explore whether lysine-rich modified γ -zein was expressed and 10 accumulated in endosperm cells, stage 17 DAP grains were bombarded with DNA containing sequences coding for the protein of the four constructs (Figure 3) under the control of the CaMV promoter (P20 γ Z and H20 γ Z) and the γ -zein promoter (H45 γ Z and N13 γ Z). Constructs including antisense promoters or free of promoters were used as controls. After 24 hours of endosperm transformation, the 15 total proteins were extracted and the expression of modified γ -zein was tested by immunoblotting using the α PL antibody. Figure 6A shows that the chimera genes of γ -zein containing the (Pro-Lys)_n insertion after the Pro-X domain (P20 γ Z) or replacing it (H45 γ Z and H30 γ Z) were strongly expressed and the translation products accumulated efficiently in the endosperm cells (Figure 6A, lines 3, 4 and 20 5). For each line, the protein extracts corresponded to about 1/3 of one bombarded endosperm, enabling it to be estimated that the quantity of modified proteins P20 γ Z, H30 γ Z and H45 γ Z per endosperm reached a nanogram level. Further, no quantitative difference between the level of expression of chimera 25 genes under the control of the CaMV promoter and the γ -zein promoter was observed, confirming the results described above obtained with reporter proteins GUS and LUC (Figure 5). It should be noted that the α PL antibody recognised a protein of about 30 kD present in the total protein extracts, even in non transformed endosperms (see the weak band present in the four lines of Figure 6A). A sequential protein extraction procedure established that this protein was 30 not a protein reserve which was soluble in an aqueous medium.

Figure 6A (line 2) shows that no trace of the N13 γ Z protein could be detected, indicating that the corresponding chimera gene was not expressed in the endosperm cells or that the N13 γ Z protein had degraded. The RNAs of endosperms transformed with the DNAs coding for the H45 γ Z and N13 γ Z proteins and the RNAs of non transformed endosperms were analysed. From the total RNAs, the cDNAs were prepared and amplified by PCR using specific primers. Figure 6B shows the Southern blot analysis of three cDNA samples hybridised with an oligonucleotide coding for a sequence K(Pro-Lys)₄ used as a probe. The results indicated that the N13 γ Z gene was correctly expressed (Figure 6B, line 3). The presence of bands in the H45 γ Z and N13 γ Z samples but not in the non transformed endosperms, has suggested that the N13 γ Z protein was degraded during the 24 hours of incubation. From these observations, the inventors have concluded that the insertion site for lysine-rich sequences was critical for the stability of the modified γ -zein.

15 **Lysine-enriched γ -zein is accumulated in protein bodies**

Apart from the lysine content in the Pro-X sequences, the P20 γ Z, H30 γ Z and H45 γ Z proteins had common characteristics with the wild type γ -zein: they had the signal peptide, the N-terminal tandem repeat and the cysteine-rich C-terminal region in common. It appeared important to determine whether these domains remained completely functional preserving targeting and formation of the protein bodies or whether the lysine-rich sequences created a special environment in which these properties could be perturbed. To test this, an investigation was made as to whether the modified γ -zeins were capable of accumulating in protein bodies. A sub-cellular fractionation was carried out with transformed endosperms. 20 Homogenates of bombarded endosperms were charged onto discontinuous sucrose gradients (20%, 50% and 70% of sucrose) and all of the fractions collected were analysed by immunoblotting. P20 γ Z, H30 γ Z and H45 γ Z sedimented on the protein body fraction and no significant quantity of these proteins was detected either in the supernatant or in the microsomal fraction (Figure 7A, lines 2, 2 and 3). While 25 the in-vitro experiments previously carried out (Figure 4A) had established that the 30

newly synthesised modified γ -zeins underwent translocation in canine microsomes, the test in this case was whether the modified proteins expressed *in-vivo* in endosperm cells underwent translocation in the membrane of the endoplasmic reticulum and remained inside protein bodies derived from the endoplasmic reticulum. For this reason, isolated protein bodies were digested with K proteinase in isotonic buffers (containing 20% of sucrose) or after an osmotic shock in water (Figure 7B). Proteins protected against proteolytic degradation by enzymes can be surrounded by a membrane and treatment with detergent or hypotonic solutions results in digestion of the proteins (Walter and Blobel, 1983, Method Enzymol. 96, 84-93). A comparison of the band intensities after digestion with K proteinase in media comprising sucrose or water revealed that the P20 γ Z, H30 γ Z and H45 γ Z proteins were protected from digestion in isotonic buffers (lines 1, 3 and 5) but were partially digested in water (lines 2, 4 and 6).

Expression of modified genes of γ -zein in the cells of the sub-aleuronic layer of the endosperm by biolistic bombardment resulted in the observation that lysine-rich γ -zeins were accumulated to a great extent with the exception of the case where the lysine-rich sequences were positioned 5 residues upstream of the C-terminal extremity of the γ -zein polypeptide. From this expression and immunocytochemical studies on isolated protein bodies, the inventors have demonstrated that lysine-rich γ -zeins are properly accumulated in these organelles and are co-localised with the endogenous γ -zein and α -zein proteins.

Protein bodies isolated from P20 γ Z endosperms were examined by immunogold type labelling and electron microscopy. On ultra fine sections incubated with the α PL antibody (Figure 8A), the gold labelling was detected inside the protein bodies, indicating that the lysine-rich protein P20 γ Z was accumulated inside these organelles. In sections incubated only with α PL antibody, immunolabelling took place only on some protein bodies (containing lysine-rich γ -zein), the large proportion of the isolated protein bodies were not immunolabelled with α PL antibodies as they corresponded to non transformed endosperm cells. To determine whether the lysine-rich γ -zein was co-localised

with the α -zeins and γ -zeins, a double labelling using immuno-electron microscopy was carried out on isolated protein bodies using the α Z and α PL antibodies (Figure 8B) and α G2 and α PL antibodies (Figure 8C and D). Figure 8B shows a micrograph of the transverse section of two protein bodies labelled with α PL antibody (15 nm gold particle) and with the α Z antibody (5 nm gold particle). The result of immunostaining showed that the P20 γ Z protein was accumulated in the protein bodies and co-localised with the α -zein (see the extent of labelling of the α -zein over the whole surface of the protein body). Further, tangential sections (Figure 8B, see arrows) and transverse sections (Figure 8D) of protein bodies were 5 incubated with the α PL antibody (15 nm gold particle) and with the α G2 antibody (5 nm gold particle). In the two cases, the P20 γ Z protein was co-localised with the γ -zein polypeptides. It was noted that the tangential sections of the protein body (Figure 8A, C see arrows), was easily distinguished from the transverse sections of 10 the protein body in that the former had a higher electron density and the γ -zein labelling extended over the whole section. In contrast, the transverse sections had a lower density and the γ -zein labelling was localised on the membrane surrounding 15 the protein body. In both cases, the labelling localisation of the lysine-rich γ -zein followed that of the endogenous γ -zein.

B) Preparation of genetically modified plants expressing lysine-rich γ -zeins

1) Production and use of maize callus as a target for genetic transformation

Genetic transformation of maize, regardless of the method used (electroporation; *Agrobacterium*, microfibres, particle cannon) generally requires the use of undifferentiated cells in rapid division which have conserved an ability to regenerate whole plants. This type of cell constitutes the embryogenic friable 20 callus (type II) of maize.

These calli were obtained from immature embryos of the Hi II or (A188 x B73) genotype using the method and media described by Armstrong (Maize Handbook; (1994) M. Freeling, V. Walbot Eds; pp 665-671). The calli obtained were multiplied and maintained by successive subculturing every fortnight 25 onto the initiation medium.

Plantlets were then regenerated from these calli by modifying the hormonal and osmotic balance using the method described by Vain et al., (Plant cell Tissue and Organ Culture (1989 18: 143-151). These plants were then acclimatised under glass where they could be crossed or self-fertilised.

5 **2) Use of particle cannon for genetic transformation of maize**

The above paragraph described the production and regeneration of cell lines necessary for transformation; this section describes a genetic transformation method leading to stable integration of modified genes into the plant genome. This method is based on the use of a particle cannon identical to that described by J. 10 Finer (Plant Cell Report (1992) 11: 323-328); the target cells were fragments of calli described in paragraph 1. 4 hours before bombardment these fragments, with a surface area of 10 to 20 mm², were disposed, in an amount of 16 fragments per dish in the centre of a petri dish containing a culture medium identical to the initiation medium, with an addition of 0.2 M of mannitol + 0.2 M of sorbitol. 15 Plasmids carrying the genes to be introduced were purified on a Qiagen® column in accordance with the manufacturer's instructions. They were then precipitated onto tungsten particles (M10) following the protocol described by Klein (Nature (1987) 327: 70-73). The coated particles were projected against the target cells using a cannon and following the protocol described by J. Finer (Plant Cell Report (1992) 20 11: 323-328).

The bombarded dishes of calli were then sealed with Scellofrais® then cultivated at 27°C in the dark. The first subculture took place 24 h later then every fortnight for 3 months to a medium identical to the initiation medium with a selective agent added, the nature and concentration of which could be varied 25 depending on the gene used (see paragraph 3). The selective agents which could be used generally consisted of active compounds of certain herbicides (Basta®, Round Up®) or certain antibiotics (Hygromycin, Kanamycin...).

After three months or sometimes earlier, calli were obtained the growth of which was not inhibited by the selective agent, normally and mainly composed of 30 cells resulting from division of a cell which had integrated one or more copies of

the selection gene into its genotype. The frequency of producing such calli was about 0.8 calli per bombarded dish.

These calli were identified, individualised, amplified then cultivated so as to regenerate plantlets (see paragraph 1). In order to avoid any interference with non 5 transformed cells, all of these operations were carried out on culture media containing the selective agent.

The regenerated plants were acclimatised then cultivated under glass where they could be crossed or self-fertilised.

3) Use of bar gene to produce genetically modified maize plants which have 10 incorporated and which express the H45 γ Z gene

The bar gene from *Streptomyces hygroscopicus* codes for a phosphinothricin acetyl transferase (PAT) which inactivates the active phosphinothricin molecule of the herbicide Basta[®] by acetylation. Cells with this gene are thus rendered resistant to this herbicide and can be selected by using it.

15 For the cereal transformation, the coding sequence of the bar gene is under the control of a regulating region enabling strong and constitutive expression in plant cells. Such a region is advantageously constituted by the promoter and the first intron of the actin gene of rice as described by McElroy (Mol. Gen. Genet. (1991) 231: 150-160).

20 This chimeral gene is cloned on a plasmid enabling its amplification by *Escherischi Coli*. After amplification then purification on a Qiagen[®] column, this plasmid (pDM 302 Cao (Plant Cell Report (1992) 11: 586-591) can be used for genetic transformation of maize using, for example, the method described in the previous example. In this case, 2 mg/L of phosphinothricin was added to culture 25 media intended to select transformed cells.

To introduce the H45 γ Z gene, a co-transformation technique is advantageously used: the selection gene (bar) and gene of interest (H45 γ Z) were carried by independent plasmids. When using a particle cannon, the plasmids were co-precipitated onto tungsten particles, the total quantity of DNA precipitated on 30 the particles remaining identical to that used in the standard protocol (5 μ g of

DNA per 2.5 mg of particles), each plasmid representing about half of the total weight of DNA used.

The experiment shows that with this method, co-integration of the plasmids in the plant cells is the most frequent event (of the order of 90%) i.e., practically 5 every plant which had integrated the bar gene and been selected by its use also carried the H45 γ Z gene. The level of co-expression (percentage of selected plants expressing the H45 γ Z gene) was normally of the order of 70%.

The genes thus introduced were generally linked in the genetic sense, thus 10 gene H45 γ Z could advantageously be followed through its descendants because of its resistance to the herbicide closely associated with it.

The quantity of modified protein was determined using the methods described in Example A, in particular by immunoblotting onto protein extracts from immature or mature maize grains, removed as a pool from plants resistant to Basta[®].

15 4) **Example explaining the step of introducing transgenes, in particular the gene coding for H45 γ Z, to modify the maize opaque-2 phenotype**

Improving opaque-2 maize by introgression of the lysine-rich γ -zein.

Transformed plants described in the previous example, with both a 20 resistance to Basta and expressing a lysine-rich γ -zein, were used. Their pollen was used to fertilise opaque-2 maize plants from the W64Ao2 line which contained only a single γ -zein gene. This line was obtained from the Maize Stock Center. The plants and its F1 descendants were selected for their resistance to Basta and then self-fertilised. The F2 grains produced were analysed for the opaque phenotype on a light table and opaque or vitreous grains were sown and evaluated 25 for Basta resistance. In the case when opaque grains are sensitive to Basta, introduction of the lysine-enriched γ -zein into the plant under consideration has been demonstrated to complement the opaque-2 phenotype.

In these Basta resistant plants, o2/o2 genotype individuals with only one γ -zein gene on chromosome 7 were selected using molecular probes coding for the 30 opaque-2 gene and for the γ -zein. These latter revealed polymorphic restriction

fragments and only individuals with the patron type of the W64o2 line were retained (Lopes M. A. et al., 1995, Mol. Gen. Genet. 19: 247, 603-613).

These individuals had a lysine content which was on average equivalent to or greater than that of o2 maize. From these individuals, any introgression in 5 ELITE varieties, with a "high lysine content" character was observed by determining the resistance to BASTA and the presence of the o2 allele detected by RFLP.

5) Expression of lysine-enriched γ -zeins in *Arabidopsis thaliana*

In order to obtain stable transformation, plasmid constructs P20 γ Z and 10 pH30 γ Z cloned in the Bluescript KS (-) plasmid were inserted in the form of HincII/XbaI fragments in the binary vector pBin19 (Bevan, M. Nucl. Acids Res. 12: 8711-8721 (1984)), containing the 35S promoter of the cauliflower mosaic virus (CaMV) and formation signals for the 3' end and polyadenylation of the octopine synthetase gene (ocs). The new plasmids were termed p19P20 γ Z and p19H30 γ Z 15 (Figure 12).

The binary vectors containing the sequences coding for the proteins P20 γ Z and H30 γ Z (p19P20 γ Z and p19H30 γ Z) were transferred to the LBA4404 strain of Agrobacterium tumefaciens. Ecotype RLD *Arabidopsis* plants were transformed using the method described by Valvekens D., Van Montagu, M and van 20 Lijsebettens, M. ((1988) Proc. Natl. Acad. Sci. USA 85: 5536-5540). For each construct, 10 transgenic plants were screened by immunoblot analysis using an antiserum obtained against the γ -zein (α G2, Ludevid et al. 1985). The plants containing the highest amounts (corresponding to about 0.1% of the total quantity 25 of proteins present in *Arabidopsis* leaves) of the transgenic products in generation F1 were selected to obtain generation F2. These plants were also selected for expression of the desired protein.

Whole transgenic plants, selected in a medium containing kanamycin, were homogenised in liquid nitrogen. The transgenic proteins were selectively extracted with a solution containing ethanol/ 0.125 N hydrochloric acid HCl in a proportion 30 of 3:1 (v/v) with 5% of mercaptoethanol and protease inhibitors. The proteins

extracted with this solution were precipitated in 5 volumes of acetone and analysed by SDS-PAGE and immunoblotting. The protein extracts from non transgenic plants were used as controls. The proteins resulting from insertion of K(P-K)₄ sequences in the γ -zein were properly expressed in Arabidopsis thaliana plants
5 using the constitutive promoter 35S from CaMV. On the immunoblots, antibodies α G2 and α PL recognised electrophoresis bands corresponding to proteins P20 γ Z and H30 γ Z. These bands migrated with apparent molecular weights in accordance with those which were previously observed in the in-vitro translation/translocation experiments (30 kD and 26 kD respectively). As observed in the transgenic
10 Arabidopsis plants expressing γ -zein (Geli et al., Plant Cell 6: 1911-1922 (1994)), the proteins P20 γ Z and H30 γ Z migrated in the form of two electrophoresis bands, namely the bands corresponding to 36 and 30 kD for P20 γ Z and the bands corresponding to 32 and 26 kD for H30 γ Z. The higher bands could correspond to products which have undergone post-translational modifications. Such a post-
15 translational modification was not detected in the transformed maize endosperms. This result suggests that the modification would appear when these proteins are expressed in a heterologous system such as Arabidopsis thaliana.

6) Expression of recombinant lysine-enriched γ -zeins in maize

Method

20 After obtaining transgenic plants, they were crossed with a non transformed male line. As a result, 50% of the grain harvested in the case of unilocus insertion will be transgenic. With the aim of analysing the lysine-enriched γ -zeins in the transgenic plants, the proteins were extracted from 6 grains per transformant.

The endosperms were dissected by removing the embryos and pericarps from the grains. The endosperms were ground and 50 mg of flour was used for selective extraction. Previously the α -zeins were extracted by three treatments with 70% ethanol. After centrifugation, the ethanol was vacuum evaporated. The proteins which were insoluble in ethanol (principally the γ -zeins and lysine-enriched γ -zeins) were extracted from the residue with a Laemli buffer containing 10% of
25 mercaptoethanol (100 μ l of buffer per 10 mg of flour). The total proteins were

then analysed by staining with silver (Morrissey, J. H. 1981, Ann. Biochem. Vol. 117, p 307-310). The γ -zeins and lysine-enriched γ -zeins were analysed by immunoblot using α G2 (dilution 1/2000) and α PL (dilution 1/500) antibodies respectively. An anti-rabbit antibody conjugated with alkaline phosphatase was used as the secondary antibody in the immunoblot. The extracts were diluted to enable them to be charged onto SDS-PAGE in accordance with the analytical method used.

Results

Accumulation of lysine-enriched γ -zein in transgenic 20 γ Z and 45 γ Z maize plants

Figure 13 shows an immunoblot of protein extracts revealed with the α PL antiserum (A, B) and the total proteins after silver staining (C). As can be seen in Figure 13A, 6 20 γ Z transgenic plants were tested with the α PL antiserum and the lysine-enriched γ -zein was expressed in transgenic plants A1 and D2 (tracks 1 and 15 6 respectively). In plant C1 (track 4), only traces of lysine-enriched γ -zein were observed. When the extracts from 6 transgenic 45 γ Z plants were charged onto gel and labelled with α PL antiserum (Figure 13B), a strong reaction with the antibody was observed for transformants B1 and C1 (tracks 3 and 4 respectively).

It should be noted that the reaction with the antibody in the extracts from endosperms from plants 45 γ Z B1 and C1 was stronger than in the extracts from plants 20 γ Z A1 and D2. This result was confirmed after staining the gels with silver (Figure 13C) where the 2 types of γ -zein: endogenic and lysine-enriched, are stained. The lysine-enriched γ -zein had an apparent molecular weight of 30 kDa and that of the endogenous γ -zein was 28 kDa. Expression of lysine-enriched γ -zein was weaker in the 45 γ Z B1 plant than in the C1 (tracks 2 and 3 respectively). In tracks 1 to 6 of Figure 13C, an identical dilution of the proteins from endosperm extracts of plants 45 γ Z and 20 γ Z were deposited on the gel. At this dilution, expression of the lysine-enriched γ -zein was detected only in endosperms from plants 45 γ Z B1 and C1. However, when a larger extract (40 μ g of proteins per track) of 20 γ Z proteins was charged onto the gel, a faint band (see arrow)

corresponding to the lysine-enriched γ -zein was detected in endosperms 20 γ Z A1 and D2. This result indicates that 45 γ Z plants accumulate many more proteins of the invention than P20 γ Z plants. This is probably due to the different activities of the promoters. 45 γ Z plants were transformed with a construct containing the γ -zein of the invention under the control of the γ -zein promoter (1.7 kb) while 20 γ Z plants were transformed with the same coding sequence but under the control of the CaMV 35S promoter. Silver staining is a general protein staining technique, but the strong brown colour is especially observed in the presence of basic proteins. Since the α -zeins had been extracted from the flour as described above, 10 they were absent during the SDS-PAGE analysis of Figure 13C.

Segregation

Since there is 50% segregation in all transgenic plants in the case of a single locus, grain by grain analysis was carried out to quantify the amount of lysine-enriched γ -zein in each transformant. The analysis was carried out only with 45 γ Z transformants which had a stronger degree of expression. Figure 14 shows the silver staining (A) and immunoblot with α PL (B) of 5 different endosperms of 45 γ Z B1 and C1. The faint electrophoretic band present on all tracks (see A, tracks 1 to 10) correspond to the endogenic γ -zein. As can be seen in Figure 14A, 2 of the 5 endosperms accumulated lysine-enriched γ -zein (see tracks 3, 4 and 6, 15 7). As a result, about half of the grains accumulated significant quantities of lysine-enriched proteins. If the fact that identical quantities of proteins were deposited on the gel was taken into account, it is observed that 45 γ Z C1 transformant had accumulated more lysine-enriched γ -zein than B1. In fact this result was in 20 agreement with that observed for silver staining of extracts mixed with endosperm (Figure 13 C, track 3). The proof of the presence of lysine-enriched γ -zein in these endosperms is underlined in Figure 14B. The immunoblot using the α PL antiserum shows that 2 endosperm extracts of 45 γ Z B1 (tracks 3 and 4) and 45 γ Z C1 (tracks 25 4 and 6) accumulated lysine-enriched γ -zein. To confirm this percentage of transgenic grains, 10 new grains of 45 γ Z C1 transformant were analysed by 30 immunoblot and using α PL antiserum (Figure 15A). As expected, about half of

the transgenic grains were detected. An immunoreactive band was observed in the endosperm extracts (tracks 1, 2, 9 and 10).

Estimation of the quantity of lysine-enriched γ -zeins in the endosperms of 45 γ Z transformants

5 α G2 is a polyclonal antiserum which recognises endogenous γ -zeins and lysine-enriched γ -zeins. The reactivity of this antiserum with extracts of 45 γ Z C1 endosperms was used to quantify the quantity of lysine-enriched γ -zeins of the invention in the endosperms of transformed plants.

Figure 15B shows the immunoblot of 5 protein extracts corresponding to 5
10 45 γ Z C1 endosperms (tracks 1 to 5). As expected, only 2 endosperms showed an immunoreaction profile characteristic of transgenic grains. The upper band of 30 kDa corresponded to lysine-enriched γ -zein (arrows on track 1 and 2) and the lower band corresponded to endogenous γ -zein. It should be noted that in the endosperms of non transgenic plants, the upper band was absent (tracks 3, 4 and 15 5). Surprisingly, it appears that the amount of endogenous γ -zein was lower in the transgenic plant extracts than in non transgenic plants (see arrows in tracks 1 and 5).

At first sight, it was observed that:

- i) in 45 γ Z C1 transgenic endosperms, the ratio of lysine-enriched γ -zein/endogenic γ -zein was 7/3. Thus the quantity of modified protein of the invention was at 20 least twice that of the endogenous protein;
- ii) the quantity of endogenic protein in the non transgenic endosperms (see tracks 3, 4 and 5) was equivalent to that of the lysine-enriched γ -zein in the transgenic endosperms (see tracks 1 and 2).

25 **7) Expression of recombinant lysine-enriched γ -zeins in wheat**

As in Example 6), it is possible to demonstrate the presence of lysine-enriched γ -zeins of the invention in wheat.

Wheat can be transformed using the method described by Weeks et al., 1993, Plant Physiol., vol 102: pages 1077-1084 or using the method described in 30 EP-A-0 709 462.

CLAIMS

1. An oligonucleotide comprising at least one concatenation coding for a polypeptide with formula $(P-K)_n$, where:
 - n is a whole number of 2 or more;
 - P represents a proline amino acid residue;
 - K represents a lysine amino acid residue;
 - the symbol “-“ represents a bond between the two amino acid residues, in particular a peptide type bond, the n $(P-K)$ units also being bonded together by such bonds, for example peptide type bonds.
- 10 2. An oligonucleotide according to claim 1, comprising a concatenation coding for a polypeptide with formula $(P-K)_n$ where n is a whole number of 3 or more, and preferably n is equal to 4, 5, 6, 7, 8, 9, 10 or 15.
- 15 3. An oligonucleotide according to claim 1 or claim 2, comprising a concatenation coding for a polypeptide with formula $(P-K)_n$, in which the sequence of n $(P-K)$ units is interrupted by one or more amino acid residues other than P or K residues.
- 20 4. An oligonucleotide according to any one of claims 1 to 3, characterized in that the concatenation coding for the polypeptide comprising the n $(P-K)$ units is completed at its 5' end and/or at its 3' end by one or more codons coding, for example, for at least one lysine residue at the N-terminal extremity of the formed polypeptide.
- 25 5. An oligonucleotide according to claim 4, characterized in that it codes for a polypeptide with formula $(P-K)$, formula $K-(P-K)_4$, or with formula $2K(P-K)_4$.
- 30 6. A recombinant nucleotide sequence comprising a concatenation of nucleotides coding for a plant protein reserve, characterized in that it further comprises an oligonucleotide according to any one of claims 1 to 5, inserted at one site of the nucleotide concatenation selected such that:
 - expression of the nucleotide sequence in a particular plant cell enables a modified protein reserve to be produced which is localised in that cell in

a manner identical to or similar to the normal protein reserve which would be expressed in the same cell under the same conditions by the corresponding normal coding nucleotide concatenation; and/or

- the modified protein reserve coded by the recombinant nucleotide sequence is immunologically recognised by antibodies produced against the corresponding normal protein reserve.

5 7. A nucleotide sequence according to claim 6, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve which is naturally low in lysine.

10 8. A nucleotide sequence according to claim 7, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve naturally produced by a plant for use in animal or human foodstuffs.

15 9. A nucleotide sequence according to claim 7 or claim 8, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve naturally produced by a plant from the cereal family.

10. A nucleotide sequence according to claim 7 or claim 8, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve naturally produced by a plant from the legume or crucifer family.

11. A nucleotide sequence according to claim 9, characterized in that the coding nucleotide concatenation it comprises codes for a maize protein reserve.

20 12. A nucleotide sequence according to claim 11, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve from the zein family.

13. A nucleotide sequence according to claim 12, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve which is maize γ -zein.

25 14. A nucleotide sequence according to claim 13, characterized in that the nucleotide concatenation coding for the maize γ -zein it contains has the sequence shown in Figure 9.

15. A nucleotide sequence according to claim 7 or claim 8, characterized in that the coding nucleotide concatenation it comprises codes for a protein reserve of a plant selected from the following: soya, sunflower, tobacco, wheat, oats, alfalfa, rice, oilseed rape, sorghum, and Arabidopsis thaliana.

5 16. A nucleotide sequence according to claim 13 or claim 14, characterized in that the oligonucleotide is inserted in place of or following the Pro-X domain or in the Pro-X domain naturally present in the maize γ -zein.

17. A recombinant nucleotide sequence, characterized in that it comprises a nucleotide sequence according to any one of claims 1 to 16 under the control of
10 an expression promoter.

18. A recombinant nucleotide sequence according to claim 17, characterized in that the promoter is a specific promoter for a given cell tissue, for example a promoter which is specific for expression in grains, and/or in the leaves of plants.

15 19. A nucleotide sequence according to claim 17, characterized in that the expression promoter is that of maize γ -zein.

20. A nucleotide sequence according to claim 17, characterized in that the expression promoter is the promoter CaMV35S.

21. A nucleotide sequence according to any one of claims 16 to 20, characterized
20 in that it codes for one of the polypeptides P20 γ Z or H45 γ Z with the sequences shown in Figures 11 and 10 respectively.

22. A cloning and/or expression vector, characterized in that it comprises, at a site which is not essential for replication, a nucleotide sequence in accordance with any one of claims 1 to 20.

25 23. A cloning and/or expression vector, characterized in that it is one of plasmids pP20 γ Z (CNCM N° I-1640), pH30 γ Z or pH45 γ Z (CNCM N° I-1639).

24. A polypeptide coded by a sequence according to any one of claims 1 to 17.

25. A lysine-enriched modified maize γ -zein, characterized in that it is coded by a nucleotide sequence according to claim 13 or claim 14.

26. A lysine-enriched modified maize γ -zein, characterized in that its amino acid sequence is modified by at least one polypeptide with formula $(P-K)_n$ or with formula $2K(P-K)_n$, where:

- n is a whole number of 2 or more;
- P represents a proline amino acid residue;
- K represents a lysine amino acid residue;
- the symbol “-“ represents a bond between the two amino acid residues, in particular a peptide type bond, the n $(P-K)$ units being bonded together by bonds, in particular peptide type bonds, said polypeptide having formula $(P-K)_n$ or $K-(P-K)_n$ being substituted for a sequence naturally present in the normal maize γ -zein or being inserted with deletion of one or more amino acids of the amino acid sequence for normal maize γ -zein, or being added to the normal γ -zein amino acid sequence, the insertion site for the polypeptide being selected such that:

- when the modified lysine-rich γ -zein is produced in a host cell, in particular in a plant cell, it is localised in identical or similar manner to the normal maize γ -zein which would be produced under the same conditions in the same host cell; and/or
- the modified maize γ -zein is recognised by antibodies directed against the normal maize γ -zein.

27. A modified maize γ -zein according to claim 26, characterized in that it is the protein P20 γ Z or the protein H30 γ Z or the protein H45 γ Z.

28. A recombinant host cell, characterized in that it comprises a nucleotide sequence according to any one of claims 1 to 17.

29. A host cell according to claim 28, characterized in that it is a bacterium, for example E. coli or Agrobacterium tumefaciens.

30. A host cell according to claim 28, characterized in that it is a plant cell.

31. A host cell according to claim 30, characterized in that it is a plant seed cell.

32. A host cell according to claim 31, characterized in that it is a cell from maize seed endosperm.

33. A host cell according to claim 32, characterized in that it contains a nucleotide sequence according to claim 13, integrated in its genome in a stable manner.

5 34. A host cell according to claim 32, characterized in that it produces a lysine-enriched modified maize γ -zein according to claim 26 or claim 27.

35. A host cell according to claim 30, characterized in that it is a soya, sunflower, tobacco, wheat, oats, alfalfa, rice, oilseed rape, sorghum or 10 Arabidopsis cell.

10 36. Seeds producing a polypeptide according to any one of claims 24 to 27.

37. A plant producing a polypeptide according to any one of claims 24 to 27.

38. A plant according to claim 37, characterized in that it is a maize plant.

39. Seeds obtained from plants according to claim 37 or claim 38.

15 40. A method of producing plants or seeds expressing a modified protein reserve, characterized in that it comprises the steps of:

20 a) transforming a plant cell with a nucleotide sequence according to any one of claims 6 to 17, or a vector according to claim 22 or claim 23, under conditions enabling the modified protein reserve coded by the nucleotide sequence to be expressed in a stable and functional manner;

b) regenerating plants from the plant cell transformed in step a), to obtain plants expressing the modified protein reserve;

25 c) if necessary, obtaining seeds from the modified plants obtained in step b).

41. A method according to claim 40, characterized in that the plant is maize and the protein reserve is γ -zein.


pP20 γ Z

FIGURE 1



pH45 γ Z

FIGURE 2






FIGURE 4




FIGURE 6

REPLACEMENT PAGE (RULE 26)




FIGURE 5




FIGURE 7




FIGURE 8

γ -Zéine

10	20	30	40	50	60
ATGAGGGTGGTGCCTGCCCTCGCTCTCCTGGCTCTCGCTGCGAGGCCACCTCCACG					
M R V L L V A L A L A L A A S A T S T					
70	80	90	100	110	120
CATACAAGCGGCGGCTGCGGCTGCCAGCCACCGCCGCCGGTTCATCTACCGCCGCCGGTG					
H T S G G C G C Q P P P P V H L P P P V					
130	140	150	160	170	180
CATCTGCCACCTCCGGTTCACCTGCCACCTCCGGTGCATCTCCCACCGCCGGTCCACCTG					
H L P P P V H L P P P V H L P P P V H L					
190	200	210	220	230	240
CCGCCGCCGGTCCACCTGCCACCGCCGGTCCATGTGCCGCCGCCGGTTCATCTGCCGCCG					
P P P V H L P P P V H V P P P V H L P P					
250	260	270	280	290	300
CCACCATGCCACTACCCCTACTCAACCGCCCCGGCCTCAGCCTCATCCCCAGCCACACCCA					
P P C H Y P T Q P P R P Q P H P Q P H P					
310	320	330	340	350	360
TGCCCCGTGCCAACAGCCGCATCCAAGCCC GTGCCAGCTGCAGGGAACCTGC GGCGTTGGC					
C P C Q Q P H P S P C Q L Q G T C G V G					
370	380	390	400	410	420
AGCACCCCCGATCCTGGGCCAGTGC GTCGAGTTCTGAGGCATCAGTGCAGCCC GACGGCG					
S T P I L G Q C V E F L R H Q C S P T A					
430	440	450	460	470	480
ACGCCCTACTGCTGCCCTCAGTGCCAGTCGTTGCCAGCAGTGTGCCAGCAGCTCAGG					
T P Y C S P Q C Q S L R Q Q C C C Q Q L R					
490	500	510	520	530	540
CAGGTGGAGCCGCAGCACCGGTACCAAGGCGATCTCGGCTGGCCTCCAGTCCATCCTG					
Q V E P Q H R Y Q A I F G L V L Q S I L					
550	560	570	580	590	600
CAGCAGCAGCCGCAAAGCGGCCAGGTGC GCGGGCTGTTGGCGGCCAGATAGCGCAGCAA					
Q Q Q P Q S G Q V A G L L A A Q I A Q Q					

FIGURE 9
REPLACEMENT PAGE (RULE 26)

610 620 630 640 650 660
| | | | | |
CTGACGGCGATGTGCGGCCTGCAGCAGCCGACTCCATGCCCTACGCTGCTGCCGGCGT
L T A M C G L Q Q P T P C P Y A A A G G

670
|
GTCCCCCACTGA
V P H -

FIGURE 9 (CONTINUED)

H45 γ Z

10	20	30	40	50	60
M R V L L V A L A L L A L A A S A T S T					
70	80	90	100	110	120
H T S G G C G C Q P P P P V H L P P P V					
130	140	150	160	170	180
H L P P P V H L P P P V H L P P P V H L					
190	200	210	220	230	240
P P P V H L P P P V H V P P P V H L P P P					
250	260	270	280	290	300
P P C H Y P T Q P P R I E F K P K P K P					
310	320	330	340	350	360
K P K E F K P K P K P K P K E F L Q P L					
370	380	390	400	410	420
Q G T C G V G S T P I L G Q C V E F L R					
430	440	450	460	470	480
H Q C S P T A T P Y C S P Q C Q S L R Q					
490	500	510	520	530	540
Q C C Q Q L R Q V E P Q H R Y Q A I F G					
550	560	570	580	590	600
L V L Q S I L Q Q P Q S G Q V A G L L					
610	620	630	640	650	660
A A Q I A Q Q L T A M C G L Q Q P T P C					

FIGURE 10

REPLACEMENT PAGE (RULE 26)

670 680 690
| | |
CCCTACGCTGCTGCCGGCGGTGTCCCCCACTGA
P Y A A A G G V P H -

FIGURE 10 (CONTINUED)

P20 γ Z



10	20	30	40	50	60
ATGAGGGTGTGCTCGTTGCCCTCGCTCTCCTGGCTCTCGCTGCGAGCGCCACCTCCACG					
M R V L L V A L A L A L A A S A T S T					
70	80	90	100	110	120
CATACAAGCGGGCTCGGGCTGCCAGCCACCGCCGCCGGTTCATCTACCGCCGCCGGTG					
H T S G G C G C Q P P P P V H L P P P P V					
130	140	150	160	170	180
CATCTGCCACCTCCGGTTCACCTGCCACCTCCGGTGCATCTCCCACCGCCGGTCCACCTG					
H L P P P V H L P P P V H L P P P P V H L					
190	200	210	220	230	240
CCGCCGCCGGTCCACCTGCCACCGCCGGTCCATGTGCCGCCGCCGGTTCATCTGCCGCCG					
P P P V H L P P P V H V P P P V H L P P					
250	260	270	280	290	300
CCACCATGCCACTACCTACTCAACCGCCCCGGCTCAGCCTCATCCCCAGCCACACCCA					
P P C H Y P T Q P P R P Q P H P Q P H P					
310	320	330	340	350	360
TGCCCCGTGCCAACAGCCGCATCCAAGGCCGTGCCAGATCGAATTCAAACCAAAGCCAAAG					
C P C Q Q P H P S P C Q I E F K P K P K K					
370	380	390	400	410	420
CCGAAGCCAAAAGAATTCCCTGCAGCCCCCTGCAGGGAACCTGCAGGGTTGGCAGCACCCCG					
P K P K E F L Q P L Q G T C G V G S T P					
430	440	450	460	470	480
ATCCTGGGCCAGTGCCTCGAGTTCTGAGGCATCAGTGCAGCCCCACGGCGACGCCCTAC					
I L G Q C V E F L R H Q C S P T A T P Y					
490	500	510	520	530	540
TGCTCGCCTCAGTGCCAGTCGTGCGGCCAGCAGTGTGCCCCAGCAGCTCAGGCAGGTGGAG					
C S P Q C Q S L R Q Q C C Q Q L R Q V E					
550	560	570	580	590	600
CCGCAGCACCGGTACCAGGCATTTCGGCTTGGCTCCAGTCCATCCTGCAGCAGCAG					
P Q H R Y Q A I F G L V L Q S I L Q Q Q					
610	620	630	640	650	660
CCGCAAAGCGGCCAGGTGCAGGGCTGTTGGCGGCCAGATAGCGCAGCAACTGACGGCG					
P Q S G Q V A G L L A A Q I A Q Q L T A					

FIGURE 11

670 680 690 700 710 720
| | | | | |
ATGTGCAGGCCTGCAGCAGCCGACTCCATGCCCTACGCTGCTGCCGGCGGTGTCCCCCAC
M C G L Q Q P T P C P Y A A A G G V P H

TGA
-

FIGURE 11 (CONTINUED)

pBin 19 P20 γ ZpBin 19 H30 γ Z

REPLACEMENT PAGE (RULE 26)

FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15

PATENT
ATTORNEY DOCKET NO: 50062/004001

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled AMINO ACID-ENRICHED PLANT PROTEIN RESERVES, PARTICULARLY LYSINE-ENRICHED MAIZE γ -ZEIN, AND PLANTS EXPRESSING SUCH PROTEINS, the specification of which

is attached hereto.
 was filed on July 27, 1998 as Application Serial No. 09/117,246
 and was amended on _____
 was described and claimed in PCT International Application No. _____
 filed on _____ and as amended under PCT Article 19 on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

Country	Serial Number	Filing Date	Priority Claimed?
PCT	PCT/FR97/00167	January 28, 1997	Yes
France	96/01004	January 29, 1996	Yes
			Yes/No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information I know to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

COMBINED DECLARATION AND POWER OF ATTORNEY


Serial Number	Filing Date	Status

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Paul T. Clark, Reg. No. 30,162, Karen L. Elbing, Reg. No. 35,238, Kristina Bieker-Brady, Reg. No. 39,109, Susan M. Michaud, Reg. No. 42,885, and Christine P. Bellon, Reg. No. 41,611.

Address all telephone calls to: Kristina Bieker-Brady, Ph.D. at 617/428-0200.

Address all correspondence to: Kristina Bieker-Brady, Ph.D. at Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Dolorès Ludevid</u>	<u>Barcelone, Spain</u>	Centro de investigacion y Desarrollo CSIC, Jordi Girona Salgado, 18-26, E- 08034 Barcelone, Spain	Spain
Signature: 	Date: <u>14/10/98</u>		


ESX

Over →

COMBINED DECLARATION AND POWER OF ATTORNEY

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Margarita Torrent</u>	<u>Barcelone, Spain</u>	Centro de investigacion y Desarrollo CSIC, Jordi Girona Salgado, 18-26, E- 08034 Barcelone, Spain	Spain
Signature: 			Date: 14/10/98

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Inaki Alvarez</u>	<u>Barcelone, Spain</u>	Centro de investigacion y Desarrollo CSIC, Jordi Girona Salgado, 18-26, E- 08034 Barcelone, Spain	Spain
Signature: 			Date: 14/10/98

Full Name (First, Middle, Last)	Residence Address (City, State, Country)	Post Office Address (Street, City, State, Country)	Citizenship
<u>Pascual Perez</u>	<u>Beaumont, France</u>	21 allée du Parc, F-63110 Beaumont, France	France
Signature: 			Date: 8/10/98